Lilly cuts Germany investment plan in half over healthcare reforms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
June 5, 2026 7:38 AM EDTMorgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,344.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Mounjaro TRx/NRx scripts for the week ending 5/29/26 were ~756,700/353,700 (vs. ~796,800/388,900 last week) per IQVIA data. Zepbound TRx/NRx scripts were ~610,800/328,300 (vs. ~659,000/360,200 last week). We see ~7% upside to '26 M+Z ests. We are monitoring the launches of LLY's Mounjaro (injectable GLP-GIP) for type 2 diabetes (T2D), and Zepbound (injectable GLP-GIP) for obesity, and Foundayo (oral GLP) given these are the company's key product cycles. Total GLP-1 TRx (LLY+Novo) grew ~32% yoy (see... More
